Featured Stories
Do Pharmaceutical Acquisitions Undermine Innovation by Disrupting Human Capital?
Antitrust authorities increasingly assess mergers through the lens of innovation, particularly in research-intensive sectors such as pharmaceuticals. In new research, Carmine Ornaghi and Lorenzo Cassi show how mergers disrupt human capital and reduce innovation in what they call manslaughter acquisitions.
Recent Authors
Featured Stories
ProMarket's newsletter
Join our weekly email newsletter.





